EXPANDED CLINICAL PROGRAM SUPPORTED BY PROMISING RESULTS FROM COMPLETED
TORONTO, Aug. 29 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced completion of a proof of concept clinical trial in Acute Myeloid Leukemia (AML), and expansion of its GTI-2040 development program in this indication, with initiation of a more advanced Phase II clinical trial with GTI-2040 and high dose Ara-C (HiDAC) in refractory and relapsed AML.
The advanced Phase II clinical trial, which is now underway, includes both an efficacy study and a novel additional study to measure intracellular target activities and pharmacological synergies between the two agents. In the first stage of the 60 patient trial, the pharmacologic and target related activity of GTI-2040 and HiDAC will be evaluated in two groups, to determine the contribution of each agent alone and in combination. The second stage of the trial will provide efficacy evaluation in a larger patient population. Lorus expects the clinical trial to be completed by the end of 2008.
The decision by Lorus to advance clinical development of GTI-2040 is
based on the encouraging results from our recently completed proof of
concept study of GTI-2040 in combination with HiDAC in patients with
refractory and relapsed AML. This clinical trial demonstrated safety and
appropriate dosing of the combination regimen and showed promising clinical
responses in patients under 60 years of age. Moreover, the clinical
responses correlated with downregulation of R2, the cellular target of
GTI-2040, and were further supported by demonstration of intracellular
GTI-2040 in circulating and bone marrow leukemic cells. Complete results
from the clinical trial are expected to be presented by the investigators
|SOURCE Lorus Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved